论文部分内容阅读
目的 :验证国产头孢克罗 (新达罗 )的临床疗效。方法 :5 2例泌尿生殖系统感染患者应用新达罗治疗 ,并与头孢拉定治疗 4 6例进行对照。结果 :治疗组与对照组临床总有效率分别为 92 .3 %和 87% ,其中单纯性泌尿系统感染有效率分别为 10 0 .0 %和 94 .1% ,复杂性尿路感染分别为 90 .5 %和 84 .2 % ,前列腺炎分别为 83 .3 %和80 .0 % ,两组疗效间差异无显著性 (P >0 .0 5 )。治疗组和对照组细菌清除率分别为 88.9%和 82 .9% (P >0 .0 5 ) ,不良反应发生率分别为 5 .8%和 8.7%。结论 :新达罗具有抗菌谱广 ,抗菌活性强 ,尿液浓度高 ,不良反应轻 ,疗效显著等特点 ,对各种泌尿生殖系统感染 ,尤其是轻、中度感染尤为适用。
Objective: To verify the clinical efficacy of domestic cefaclor (neo-Daruo). Methods: Fifty-two patients with genitourinary infection were treated with nedalot and compared with 46 patients treated with cefradine. Results: The total clinical effective rates of the treatment group and the control group were 92.3% and 87%, respectively, of which the effective rates of simple urinary tract infections were 100.0% and 94.1%, respectively, and the complicated urinary tract infections were 90 .5% and 84.2%, prostatitis were 83.3% and 80.0% respectively, there was no significant difference between the two groups (P> 0.05). The bacterial clearance rates of the treatment group and the control group were 88.9% and 82.9%, respectively (P> 0.05), and the rates of adverse reactions were 5.8% and 8.7% respectively. Conclusion: Sinodoro has wide antibacterial spectrum, strong antibacterial activity, high urine concentration, light adverse reactions, and remarkable curative effect. It is especially suitable for all genitourinary infections, especially mild and moderate infections.